Temple Buys Longévous Ahead of Wearable Debut
Deepinder Goyal’s health-tech venture Temple has acquired London-based longevity medicine practice Longévous, bringing its founders and team into the startup as it prepares for the launch of its wearable device. The acquisition was announced by Goyal in a LinkedIn post on Thursday, with financial details of the transaction not disclosed.
Under the deal, Dr Robert Mohr will join Temple as chief medical officer, while Dr Avi Roy will become head of science. Longévous will continue to operate as part of Temple, with the two founders continuing to look after its existing clients, Goyal said.
The acquisition began with a chance meeting between Goyal and Longévous founders Robert Mohr and Avi Roy at a dinner in London a few months ago. The two noticed the Temple device he was wearing and asked him about it, turning a casual exchange into a longer discussion about the science behind the product.
Related: Nvidia posts 106% revenue rise CEO defends AI
Mohr and Roy subsequently spent two months using Temple as their “daily driver” to track their activities. During that period, they worked with Temple’s science team to test Entropy and examine the data collected by the device. Goyal said they challenged Temple’s assumptions and poked holes in its vision.
Temple is now moving closer to the launch of its wearable device. Goyal said the startup has partnered with Zetwerk and Ethereal Machines to scale production, with plans to initially manufacture a few thousand units for domestic and international markets.
In a LinkedIn post on August 21, Goyal said Temple is now less than half the size of its earlier version and that pre-orders for a limited launch edition would begin soon, with shipping planned before the end of 2026.
Related: Glass architecture pushes design boundaries
Mohr is a board-certified physician with nearly two decades of clinical experience, while Roy is an Oxford-trained biomedical scientist who has worked at the intersection of longevity science and business. Their expertise will help Temple bring “clinical grade expertise” to its experiments and claims, Goyal said.
It will be significant to see how this acquisition plays out in the coming months.
